A Phase 2 interventional study of GSK2330672 and Placebo in Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline. Completed at 4 sites in United States. Open to participants aged 30 Years to 64 Years. Per ClinicalTrials.gov, last updated 2017-11-06.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · GlaxoSmithKline.
Among the 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline, this one is the 62nd largest by enrollment of the 125 interventional ones that give a count, is one of 4 that started in 2014, is one of 22 in phase 2, and was the 126th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 30 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
136 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 23 · Phase 3 29 · Phase 4 23
First in 2000; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 70 across the 125 interventional studies, 1,270 across the 10 observational. Of the 133 that completed or were terminated, 46 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK2330672 compared to sitagliptin when administered with metformin for 14 days to subjects with type 2 diabetes mellitus (T2DM). Approximately 72 male and female subjects aged 30-64 years with T2DM and currently taking metformin will be recruited for this study. Eligible subjects will begin a run-in period of 13-15 days to stabilize on metformin 850 milligram (mg) twice a day (BID). Subjects will then be randomized to GSK2330672 10 mg, 20 mg, 30 mg, 90 mg, matching placebo or open-label sitagliptin 50 mg for 14 days BID. Subjects will return for a follow-up visit 7-10 days after discharge.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 10 mg BID for 14 days.
Drug: GSK2330672 · Drug: Metformin
Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 20 mg BID for 14 days.
Drug: GSK2330672 · Drug: Metformin
Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 30 mg BID for 14 days.
Drug: GSK2330672 · Drug: Metformin
Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 90 mg BID for 14 days.
Drug: GSK2330672 · Drug: Metformin
Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by matching placebo (of GSK2330672) BID for 14 days.
Drug: Placebo · Drug: Metformin
Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by Sitagliptin 50 mg BID for 14 days. In this study, sitagliptin 50 mg BID will be provided as open-label (unblinded) study treatment.
Drug: Sitagliptin · Drug: Metformin
GSK2330672 will be available in 10 mg, 20 mg, 30 mg, and 90 mg oral solution to be administered BID for 14 days. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
Matching placebo will be available as oral solution to be administered for 14 days, BID. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
Sitagliptin will be available as film-coated tablets Tablet of 50 mg to be administered orally, BID, for 14 days
Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14
Change From Baseline in Derived Plasma Glucose Parameter Over a 24-hour Period-fasting and Weighted Mean Glucose Area Under Curve (AUC[0-24 Hour])
The change from Baseline was calculated by subtracting the Baseline values from the individual post-Baseline values. Baseline was defined as pre-dose Day -1 value. It was assessed on Baseline, Day 7 and 14. Data for fasting and weighted mean (WM) AUC(0-24 hour) glucose is provided. Statistics for least square mean is provided and participants withdrawing early were excluded. Results were based on an analysis of covariance (ANCOVA) model: change from Baseline = Baseline + treatment.
Time frame: Baseline (Day -1) and Day 14 (Fasting Pre-dose [within 15 minutes of dose], 30 minutes, 1, 1.5, 2, 4 [pre-lunch], 5.5, 10 [pre-dinner], 11.5, 14 [bed time] and 24 hours) and Day 7 (30 minutes, 2, 4 [pre-lunch], 5.5, 10 [pre-dinner], 11.5, and 24 hours)
Number of Participants With Incidence and Nature of Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition and alanine aminotransferase (ALT) \>= 3× upper limit of normal (ULN) and total bilirubin \>=2 × ULN (\>35% direct) or ALT \>=3 × ULN and international normalized ratio \>1.5.
Time frame: Up to 14 days (treatment period)
Number of Participants With Abnormal Hematology With Potential Clinical Concern (PCI)
Hematology parameters included platelet, red blood cell (RBC) count, mean corpuscular volume (MCV), neutrophils, white blood cell (WBC) count (absolute), mean corpuscular hemoglobin (MCH), lymphocytes, mean corpuscular hemoglobin concentration (MCHC), monocytes, hemoglobin, eosinophils, hematocrit and basophils. It was assessed on Baseline (pre-dose Day -1), Day 7 and 15. Data for parameters with above and below the PCI is provided.
Time frame: Up to Day 15
Number of Participants With Abnormal Clinical Chemistry With PCI
Clinical chemistry parameters included blood urea nitrogen (BUN), potassium, aspartate aminotransferase (AST), total bilirubin, direct bilirubin, creatinine, chloride, alanine aminotransferase (ALT), uric acid, fasting glucose, total carbon dioxide, gamma glutamyltransferase (GGT), albumin, sodium, calcium, alkaline phosphatase (ALP), total protein, total carbon dioxide and triglycerides. It was assessed on Baseline (pre-dose Day -1), Day 7 and 15. Data for parameters with above and below the PCI is provided. The normal range (NR) and PCI definition for abnormal parameters are: ALT (NR: 0-44, 0-32, 2-33; PCI: \>=2×upper limit of normal \[ULN\]); AST (NR: 0-40; PCI: \>=2× ULN) and total bilirubin (NR: 0.00-20.52; PCI: \>=1.5× ULN).
Time frame: Up to Day 15
Number of Participants With Abnormal Urinalysis Data
Urinalysis included urine occult blood: trace to 3+, glucose: negative to 3+, protein: negative to 2+ and ketones: trace to negative by dipstick and microscopic examination included cast, cellular cast, granular cast, hyaline cast (none seen to 1) and RBC: 0-2, 3-10, 11-30, \>30, WBC: none seen, 0-5, 1, 2, 4, \<5, 6-10, 11-30, 19, \>30). The plus sign increases with a higher level of occult blood, glucose, ketones, proteins, RBC, WBC in the urine: 1+: slightly positive, 2+: positive, 3+: high positive. Participants were categorized as none seen or 1 based on the absence or presence, respectively, of cast, cellular cast, granular cast and hyaline cast. Higher value indicates higher abnormality.
Time frame: Baseline (pre-dose Day -1), Day 7 and 15
Summary of Urinalysis Data-mean Specific Gravity
Data for mean specific gravity is provided. Specific gravity is a measure of the amount of material dissolved in the urine. Specific gravity is the ratio of the density (mass of a unit volume) of a substance to the density (mass of the same unit volume) of a reference substance. Normal urine has a specific gravity between 1.010 and 1.020.
Time frame: Baseline (pre-dose Day -1), Day 7 and 15
Summary of Urinalysis Data-mean pH
Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).
Time frame: Baseline (pre-dose Day -1), Day 7 and 15
Number of Participants With Abnormal Electrocardiogram (ECG) Findings Any Time Post-Baseline
Single 12-lead ECGs was obtained at each time point during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals. It was assessed on Baseline (pre-dose Day -1), Day 7 and 15. Participants with normal, abnormal not clinically significant and abnormal clinically significant ECG is presented.
Time frame: Up to Day 15
Change From Baseline in Vital Signs Assessments-temperature
The change from Baseline was calculated by subtracting the Baseline values from the individual post-Baseline values. Baseline was defined as pre-dose Day -1 value.
Time frame: Baseline (pre-dose Day -1) and, Day 7, 15
Change From Baseline in Vital Signs Assessments-systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
The change from Baseline was calculated by subtracting the Baseline values from the individual post-Baseline values. Baseline was defined as pre-dose Day -1 value.
Time frame: Baseline (pre-dose Day -1) and Day 7, 15
Change From Baseline in Vital Signs Assessments-heart Rate
The change from Baseline was calculated by subtracting the Baseline values from the individual post-Baseline values. Baseline was defined as pre-dose Day -1 value.
Time frame: Baseline (pre-dose Day -1) and Day 7, 15
Number of Bowel Movements (Stool Frequency) as Rated Using the Bristol Stool Form Scale (BSFS) Across Days 1 to 14
The site staff classified participant's stools and record the date and time of occurrence after any bowel movement that occurs while participants were in residence in the clinic. BSFS is scale between type 1-7, it measured the shape of the stool, type 1: separate hard lumps, like nuts; type 2: sausage shaped but lumpy; type 3: like a sausage or snake but with cracks on its surface; type 4: like a sausage or snake, smooth and soft; type 5: soft blobs with clear cut edges; type 6: fluffy pieces with ragged edges, a mushy stool and type 7: watery, no solid pieces. Participants were discharged after they have had at least one bowel movement after the Day 14 dosing and after the investigator/designee had reviewed the Day 15 end of study questions.
Time frame: Up to Day 15 (administered after every in-house bowel movement)
Number of Events With the Rating on Quality of Stools as Rated Using the BSFS Across Days 1 to 14
The site staff classified participant's stools and record the date and time of occurrence after any bowel movement that occurs while participants were in residence in the clinic. BSFS is scale between type 1-7, it measured the shape of the stool, type 1: separate hard lumps, like nuts; type 2: sausage shaped but lumpy; type 3: like a sausage or snake but with cracks on its surface; type 4: like a sausage or snake, smooth and soft; type 5: soft blobs with clear cut edges; type 6: fluffy pieces with ragged edges, a mushy stool and type 7: watery, no solid pieces. Participants were discharged after they have had at least one bowel movement after the Day 14 dosing and after the investigator/designee had reviewed the Day 15 end of study questions.
Time frame: Up to Day 15 (administered after every in-house bowel movement)
Number of Participants With Gastrointestinal Tolerability Assessments as Rated Using the Gastrointestinal Symptom Rating Scale (GSRS; With Worsening Symptoms >=2 Levels)
GSRS is a rating scale consisting of 15 items. Each item was scored from 1: no discomfort at all, 2: minor discomfort, 3: mild discomfort, 4: moderate discomfort, 5: moderately severe discomfort, 6: severe discomfort, 7: very severe discomfort. The overall GSRS score is the mean of these 15 items, varying from 1 to 7; a score of 1 indicates that no symptoms are present, and a score of 7 indicates the worst possible degree of all symptoms. A higher score relative to Baseline indicates worsening of severity. There were 5 defined syndrome scores and 1 overall score that was derived by computing the mean of the scores for specific subsets of questions as indicated below: abdominal pain (1, 4, 5); reflux syndrome (2, 3); diarrhea syndrome (11, 12, 14); indigestion syndrome (6, 7, 8, 9); constipation syndrome (10, 13, 15) and overall GSRS (1-15). The data is presented for participants with worsening of symptoms in \>=2 levels.
Time frame: Day 7 and 14
Number of Participants With Fecal Occult Blood Monitoring for Symptomatic or Visible Gastrointestinal Bleeding or Asymptomatic Occult Bleeding
Testing cards were provided to participants for assessments. Participants with abnormal not clinically significant and abnormal clinically significant is presented. The Day -1 sample was obtained any time starting Day -2 and prior to GSK2330672 dosing on Day 1. The Day 14 sample was collected any time after dosing on Day 14 and prior to discharge on Day 15.
Time frame: Up to Day 15
PK Parameters for Metformin Steady State PK Parameters When Co-dosed With GSK2330672, Sitagliptin or Placebo-maximum Observed Concentration (Cmax)
The first occurrence of the maximum observed plasma concentration determined directly from the raw concentration-time data. Statistics for geometric least square mean provided.
Time frame: Fasting pre-dose (within 15 minutes of dose), 30 minutes, 1, 1.5, 2, 3, 4 (pre-lunch), 5.5, 8, 10 hours (pre-dinner) on Day 14
PK Parameters for Metformin Steady State PK Parameters When Co-dosed With GSK2330672, Sitagliptin or Placebo-time of Occurrence of Cmax (Tmax)
The time at which Cmax observed was determined directly from the raw concentration-time data.
Time frame: Fasting pre-dose (within 15 minutes of dose), 30 minutes, 1, 1.5, 2, 3, 4 (pre-lunch), 5.5, 8, 10 hours (pre-dinner) on Day 14
PK Parameters for Metformin Steady State PK Parameters When Co-dosed With GSK2330672, Sitagliptin or Placebo-area Under the Concentration-time Curve Over the Dosing Interval of 10 Hours (AUC[0-10])
PK population. Only those participants available at the specified time points were analyzed.
Time frame: Fasting pre-dose (within 15 minutes of dose), 30 minutes, 1, 1.5, 2, 3, 4 (pre-lunch), 5.5, 8, 10 hours (pre-dinner) on Day 14
Ratio to Baseline in Fasting Low-density Cholesterol (LDL) Cholesterol, High-density Cholesterol (HDL) Cholesterol, Total Cholesterol, Non-HDL Cholesterol and Triglycerides
Data for fasting low-density cholesterol (LDL) cholesterol, high-density cholesterol (HDL) cholesterol, total cholesterol, non-HDL cholesterol and triglycerides is presented. Participants withdrawing early were excluded. Results were based on an ANCOVA model: Log(post-Baseline) - Log(Baseline) = Log(Baseline) + treatment + concomitant use of lipid lowering drugs.
Time frame: Baseline (pre-dose Day -1) and Day 7, 14
Ratio to Baseline in Fasting Apolipoprotein B
Data for fasting apolipoprotein B is presented. Participants withdrawing early were excluded. Results were based on an ANCOVA model: Log(post-Baseline) - Log(Baseline) = Log(Baseline) + treatment + concomitant use of lipid lowering drugs.
Time frame: Baseline (pre-dose Day -1) and Day 7, 14
Sitagliptin Steady State PK Parameters When Co-dosed With Metformin-Cmax Following the First and Second Sitagliptin Doses
The first occurrence of the maximum observed plasma concentration determined directly from the raw concentration-time data following the first and second dose of sitagliptin on Day 14 (Cmax1 and Cmax2).
Time frame: Fasting pre-dose (within 15 minutes of dose), 1, 2, 3, 4 (pre-lunch), 10 (pre-dinner), 13 and 14 hours (bed time) on Day 14
Sitagliptin Steady State PK Parameters When Co-dosed With Metformin-Tmax Following the First and Second Sitagliptin Doses
The time at which Cmax was observed by determining directly from the raw concentration-time data following the first and second dose of sitagliptin on Day 14 (Tmax1 and Tmax2). If data permits, Tmax2 was defined as the time of Cmax following the second dose of sitagliptin.
Time frame: Fasting pre-dose (within 15 minutes of dose), 1, 2, 3, 4 (pre-lunch), 10 (pre-dinner), 13 and 14 hours (bed time) on Day 14
Sitagliptin Steady State PK Parameters When Co-dosed With Metformin-AUC(0-10)
The AUC(0-10) following the first dose and prior to the second dose of sitagliptin was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations.
Time frame: Fasting pre-dose (within 15 minutes of dose), 1, 2, 3, 4 (pre-lunch), 10 (pre-dinner) on Day 14
The study was conducted from 27 August 2014 to 30 January 2015. After interim analysis of safety, tolerability, pharmacodynamic and/or pharmacokinetic (PK) data, GSK2330672 10 and 20 milligram (mg) doses were dropped and GSK2330672 60 mg was added.
| Milestone | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID | Run-in Only |
|---|---|---|---|---|---|---|---|---|
| Started | 13 | 5 | 5 | 9 | 9 | 10 | 13 | 6 |
| Completed | 12 | 4 | 5 | 9 | 8 | 9 | 13 | 0 |
| Not completed | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 6 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Did not meet continuation criteria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
The change from Baseline was calculated by subtracting the Baseline values from the individual post-Baseline values. Baseline was defined as pre-dose Day -1 value. It was assessed on Baseline, Day 7 and 14. Data for fasting and weighted mean (WM) AUC(0-24 hour) glucose is provided. Statistics for least square mean is provided and participants withdrawing early were excluded. Results were based on an analysis of covariance (ANCOVA) model: change from Baseline = Baseline + treatment.
| Mg/deciliter | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID |
|---|---|---|---|---|---|---|---|
| Fasting, Day 7 | -6.58 ± 16.357 | -8.25 ± 6.500 | -1.40 ± 23.050 | -38.56 ± 24.744 | -34.38 ± 19.398 | -24.78 ± 13.414 | -24.54 ± 33.955 |
| Fasting, Day 14 | -10.00 ± 19.207 | -22.75 ± 11.354 | -16.20 ± 28.709 | -48.67 ± 32.650 | -36.13 ± 23.117 | -40.22 ± 19.156 | -38.38 ± 16.439 |
| WM AUC(0-24 hour), Day 7 | 3.91 ± 20.668 | -12.14 ± 11.828 | -7.01 ± 17.262 | -25.33 ± 25.819 | -21.47 ± 18.419 | -14.84 ± 18.569 | -26.63 ± 23.610 |
| WM AUC(0-24 hour), Day 14 | -9.94 ± 18.458 | -22.44 ± 15.928 | -17.80 ± 16.990 | -37.48 ± 32.909 | -32.22 ± 22.948 | -45.54 ± 21.010 | -35.85 ± 20.233 |
An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition and alanine aminotransferase (ALT) \>= 3× upper limit of normal (ULN) and total bilirubin \>=2 × ULN (\>35% direct) or ALT \>=3 × ULN and international normalized ratio \>1.5.
| Participants | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID |
|---|---|---|---|---|---|---|---|
| Any AE | 9 | 4 | 5 | 5 | 8 | 8 | 8 |
| Any SAE | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Hematology parameters included platelet, red blood cell (RBC) count, mean corpuscular volume (MCV), neutrophils, white blood cell (WBC) count (absolute), mean corpuscular hemoglobin (MCH), lymphocytes, mean corpuscular hemoglobin concentration (MCHC), monocytes, hemoglobin, eosinophils, hematocrit and basophils. It was assessed on Baseline (pre-dose Day -1), Day 7 and 15. Data for parameters with above and below the PCI is provided.
| Participants | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID |
|---|---|---|---|---|---|---|---|
| Number of Participants With Abnormal Hematology With Potential Clinical Concern (PCI) | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Clinical chemistry parameters included blood urea nitrogen (BUN), potassium, aspartate aminotransferase (AST), total bilirubin, direct bilirubin, creatinine, chloride, alanine aminotransferase (ALT), uric acid, fasting glucose, total carbon dioxide, gamma glutamyltransferase (GGT), albumin, sodium, calcium, alkaline phosphatase (ALP), total protein, total carbon dioxide and triglycerides. It was assessed on Baseline (pre-dose Day -1), Day 7 and 15. Data for parameters with above and below the PCI is provided. The normal range (NR) and PCI definition for abnormal parameters are: ALT (NR: 0-44, 0-32, 2-33; PCI: \>=2×upper limit of normal \[ULN\]); AST (NR: 0-40; PCI: \>=2× ULN) and total bilirubin (NR: 0.00-20.52; PCI: \>=1.5× ULN).
| Participants | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID |
|---|---|---|---|---|---|---|---|
| ALT, high | 1 | 0 | 2 | 2 | 2 | 1 | 1 |
| AST, high | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Total Bilirubin, hgh | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Urinalysis included urine occult blood: trace to 3+, glucose: negative to 3+, protein: negative to 2+ and ketones: trace to negative by dipstick and microscopic examination included cast, cellular cast, granular cast, hyaline cast (none seen to 1) and RBC: 0-2, 3-10, 11-30, \>30, WBC: none seen, 0-5, 1, 2, 4, \<5, 6-10, 11-30, 19, \>30). The plus sign increases with a higher level of occult blood, glucose, ketones, proteins, RBC, WBC in the urine: 1+: slightly positive, 2+: positive, 3+: high positive. Participants were categorized as none seen or 1 based on the absence or presence, respectively, of cast, cellular cast, granular cast and hyaline cast. Higher value indicates higher abnormality.
| Participants | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID |
|---|---|---|---|---|---|---|---|
| Urine Occult Blood, Day -1, Trace | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Urine Occult Blood, Day -1, small | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Urine Occult Blood, Day-1, 3+ | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Urine Occult Blood, Day 7, Trace | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| Urine Occult Blood, Day 7, Trace intact | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Urine Occult Blood, Day 7, small | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Urine Occult Blood, Day 7, 1+ | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Urine Occult Blood, Day 15, Trace | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Urine Occult Blood, Day 15, small | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Urine Occult Blood, Day 15, 2+ | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urine Microscopy-Casts, Day 7, none seen | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Urine Microscopy-Cellular Casts, Day -1, none seen | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Urine Microscopy-Cellular Casts, Day 7, none seen | 0 | 0 | 0 | 0 | 2 | 0 | 1 |
| Urine Microscopy-Cellular Casts, Day 15, none seen | 0 | 0 | 0 | 0 | 2 | 0 | 1 |
| Urine Microscopy-Granular Casts, Day -1, none seen | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Urine Microscopy-Granular Casts, Day 7, none seen | 0 | 0 | 0 | 0 | 2 | 0 | 1 |
| Urine Microscopy-Granular Casts, Day 15, none seen | 0 | 0 | 0 | 0 | 2 | 0 | 1 |
| Urine Glucose, Day -1, Trace | 1 | 0 | 1 | 1 | 1 | 2 | 0 |
| Urine Glucose, Day -1, 1+ | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Urine Glucose, Day -1, 2+ | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Urine Glucose, Day -1, 3+ | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Urine Glucose, Day 7, Trace | 0 | 0 | 0 | 2 | 1 | 1 | 1 |
| Urine Glucose, Day 7, 1+ | 1 | 0 | 1 | 0 | 0 | 0 | 1 |
| Urine Microscopy-Hyaline Casts, Day -1, none seen | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Urine Microscopy-Hyaline Casts, Day 7, None seen | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Urine Microscopy-Hyaline Casts, Day 7, 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Urine Microscopy-Hyaline Casts, Day 15, none seen | 0 | 0 | 0 | 0 | 2 | 0 | 1 |
| Urine Ketones, Day 7, Trace | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Urine Protein, Day -1, 1+ | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Urine Protein, Day 7, 2+ | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Urine Protein, Day 15, Trace | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Urine Protein, Day 15, 1+ | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Urine Microscopy-RBC, Day -1, none seen | 2 | 0 | 0 | 1 | 0 | 0 | 1 |
| Urine Microscopy-RBC, Day -1, 0-2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Urine Microscopy-RBC, Day -1, 3-10 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| Urine Microscopy-RBC, Day -1, 11-30 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Urine Microscopy-RBC, Day 7, none seen | 1 | 1 | 0 | 0 | 0 | 0 | 2 |
| Urine Microscopy-RBC, Day 7, 0-2 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Urine Microscopy-RBC, Day 15, none seen | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Urine Microscopy-RBC, Day 7, 3-10 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Urine Microscopy-WBC, Day -1, none seen | 2 | 2 | 0 | 1 | 0 | 0 | 1 |
| Urine Microscopy-WBC, Day -1, 0-5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urine Microscopy-WBC, Day -1, 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Urine Microscopy-WBC, Day -1, 4 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Urine Microscopy-WBC, Day -1, 6-10 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Urine Microscopy-WBC, Day -1, 11-30 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Urine Microscopy-WBC, Day -1, >30 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Urine Microscopy-WBC, Day 7, 0-5 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Urine Microscopy-WBC, Day 7, 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Urine Microscopy-WBC, Day 7, <5 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Urine Microscopy-WBC, Day 7, 11-30 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Urine Microscopy-WBC, Day 7, 19 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Urine Microscopy-WBC, Day 7, >30 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Urine Microscopy-WBC, Day 15, 0-5 | 1 | 0 | 1 | 1 | 0 | 0 | 0 |
| Urine Microscopy-WBC, Day 15, 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Urine Microscopy-WBC, Day 15, 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Urine Microscopy-WBC, Day 15, 4 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Urine Microscopy-WBC, Day 15, 11-30 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Urine Microscopy-WBC, Day 15, >30 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Data for mean specific gravity is provided. Specific gravity is a measure of the amount of material dissolved in the urine. Specific gravity is the ratio of the density (mass of a unit volume) of a substance to the density (mass of the same unit volume) of a reference substance. Normal urine has a specific gravity between 1.010 and 1.020.
| Ratio | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID |
|---|---|---|---|---|---|---|---|
| Day -1 | 1.0193 ± 0.00694 | 1.0182 ± 0.00581 | 1.0128 ± 0.00421 | 1.0190 ± 0.00618 | 1.0172 ± 0.00610 | 1.0189 ± 0.00780 | 1.0148 ± 0.00706 |
| Day 7 | 1.0196 ± 0.00753 | 1.0208 ± 0.00904 | 1.0184 ± 0.00896 | 1.0191 ± 0.00739 | 1.0194 ± 0.00726 | 1.0208 ± 0.00859 | 1.0160 ± 0.00790 |
| Day 15 | 1.0188 ± 0.00403 | 1.0193 ± 0.00435 | 1.0158 ± 0.00259 | 1.0132 ± 0.00471 | 1.0121 ± 0.00348 | 1.0160 ± 0.00787 | 1.0140 ± 0.00815 |
Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).
| Unit on a scale | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID |
|---|---|---|---|---|---|---|---|
| Day -1 | 5.73 ± 0.388 | 6.00 ± 0.000 | 6.10 ± 0.224 | 6.11 ± 0.220 | 5.83 ± 0.354 | 5.95 ± 0.438 | 5.85 ± 0.516 |
| Day 7 | 5.83 ± 0.389 | 5.90 ± 0.224 | 6.00 ± 0.000 | 5.89 ± 0.220 | 5.61 ± 0.486 | 5.95 ± 0.284 | 5.69 ± 0.435 |
| Day 15 | 5.88 ± 0.377 | 5.88 ± 0.250 | 6.00 ± 0.000 | 6.00 ± 0.000 | 5.72 ± 0.565 | 6.06 ± 0.167 | 5.88 ± 0.416 |
Single 12-lead ECGs was obtained at each time point during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals. It was assessed on Baseline (pre-dose Day -1), Day 7 and 15. Participants with normal, abnormal not clinically significant and abnormal clinically significant ECG is presented.
| Participants | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID |
|---|---|---|---|---|---|---|---|
| Normal | 9 | 4 | 4 | 8 | 6 | 6 | 9 |
| Abnormal not clinically significant | 4 | 0 | 1 | 1 | 3 | 4 | 4 |
| Abnormal clinically significant | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
The change from Baseline was calculated by subtracting the Baseline values from the individual post-Baseline values. Baseline was defined as pre-dose Day -1 value.
| Degree Celsius | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID |
|---|---|---|---|---|---|---|---|
| Day 7 | -0.133 ± 0.2570 | -0.280 ± 0.4764 | 0.040 ± 0.4393 | 0.033 ± 0.3937 | 0.033 ± 0.2062 | 0.010 ± 0.4458 | 0.015 ± 0.4451 |
| Day 15 | -0.208 ± 0.3370 | 0.025 ± 0.1708 | -0.040 ± 0.2966 | -0.111 ± 0.5622 | 0.056 ± 0.2744 | -0.178 ± 0.5995 | 0.062 ± 0.3404 |
The change from Baseline was calculated by subtracting the Baseline values from the individual post-Baseline values. Baseline was defined as pre-dose Day -1 value.
| Millimeters of mercury | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID |
|---|---|---|---|---|---|---|---|
| DBP, Day 7 | -0.083 ± 6.8152 | -1.600 ± 8.5323 | -6.600 ± 1.9494 | -1.556 ± 10.7948 | -4.111 ± 4.9861 | -2.700 ± 6.7007 | -2.462 ± 7.6770 |
| DBP, Day 15 | 0.750 ± 6.1070 | -2.750 ± 4.5735 | 1.800 ± 5.8481 | -1.333 ± 9.1104 | -1.667 ± 3.9370 | -2.667 ± 6.3048 | -0.769 ± 5.0852 |
| SBP, Day 7 | 2.250 ± 8.4544 | -4.000 ± 10.2225 | -15.600 ± 6.1482 | 2.222 ± 17.6973 | 1.222 ± 9.1211 | -4.300 ± 10.9245 | -5.462 ± 10.3571 |
| SBP, Day 15 | 2.167 ± 8.5049 | -4.500 ± 10.4722 | 0.600 ± 11.8870 | -5.111 ± 11.9105 | -1.000 ± 9.3541 | -2.111 ± 9.5321 | -4.385 ± 9.2334 |
The change from Baseline was calculated by subtracting the Baseline values from the individual post-Baseline values. Baseline was defined as pre-dose Day -1 value.
| Beats per minute | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID |
|---|---|---|---|---|---|---|---|
| Day 7 | -0.500 ± 8.1296 | 9.200 ± 8.2280 | 4.400 ± 7.4027 | 0.556 ± 5.2941 | 4.667 ± 4.0620 | 1.400 ± 7.0269 | -0.769 ± 6.2471 |
| Day 15 | 0.083 ± 3.1176 | 0.250 ± 6.3443 | 9.200 ± 3.1937 | -0.444 ± 8.2932 | 4.889 ± 7.4237 | 0.000 ± 8.8034 | 1.846 ± 9.1364 |
The site staff classified participant's stools and record the date and time of occurrence after any bowel movement that occurs while participants were in residence in the clinic. BSFS is scale between type 1-7, it measured the shape of the stool, type 1: separate hard lumps, like nuts; type 2: sausage shaped but lumpy; type 3: like a sausage or snake but with cracks on its surface; type 4: like a sausage or snake, smooth and soft; type 5: soft blobs with clear cut edges; type 6: fluffy pieces with ragged edges, a mushy stool and type 7: watery, no solid pieces. Participants were discharged after they have had at least one bowel movement after the Day 14 dosing and after the investigator/designee had reviewed the Day 15 end of study questions.
| Count of bowel movements | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID | Run-in Only |
|---|---|---|---|---|---|---|---|---|
| Number of Bowel Movements (Stool Frequency) as Rated Using the Bristol Stool Form Scale (BSFS) Across Days 1 to 14 | 15.2 ± 9.29 | 28.2 ± 17.47 | 38.4 ± 10.74 | 35.0 ± 18.49 | 37.3 ± 30.72 | 35.9 ± 21.67 | 15.0 ± 10.96 | — |
The site staff classified participant's stools and record the date and time of occurrence after any bowel movement that occurs while participants were in residence in the clinic. BSFS is scale between type 1-7, it measured the shape of the stool, type 1: separate hard lumps, like nuts; type 2: sausage shaped but lumpy; type 3: like a sausage or snake but with cracks on its surface; type 4: like a sausage or snake, smooth and soft; type 5: soft blobs with clear cut edges; type 6: fluffy pieces with ragged edges, a mushy stool and type 7: watery, no solid pieces. Participants were discharged after they have had at least one bowel movement after the Day 14 dosing and after the investigator/designee had reviewed the Day 15 end of study questions.
| Events | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID |
|---|---|---|---|---|---|---|---|
| BSFS scale rating, 1 event : Events | 2 | — | — | 1 | — | 1 | 2 |
| BSFS scale rating, 2 events : Events | 6 | — | 2 | 1 | — | — | 10 |
| BSFS scale rating, 3 events : Events | 28 | — | 4 | 1 | 6 | 5 | 36 |
| BSFS scale rating, 4 events : Events | 56 | 7 | 18 | 19 | 21 | 24 | 41 |
| BSFS scale rating, 5 events : Events | 30 | 2 | 8 | 26 | 9 | 30 | 26 |
| BSFS scale rating, 6 events : Events | 59 | 81 | 113 | 181 | 250 | 201 | 70 |
| BSFS scale rating, 7 events : Events | 16 | 51 | 47 | 86 | 50 | 98 | 10 |
GSRS is a rating scale consisting of 15 items. Each item was scored from 1: no discomfort at all, 2: minor discomfort, 3: mild discomfort, 4: moderate discomfort, 5: moderately severe discomfort, 6: severe discomfort, 7: very severe discomfort. The overall GSRS score is the mean of these 15 items, varying from 1 to 7; a score of 1 indicates that no symptoms are present, and a score of 7 indicates the worst possible degree of all symptoms. A higher score relative to Baseline indicates worsening of severity. There were 5 defined syndrome scores and 1 overall score that was derived by computing the mean of the scores for specific subsets of questions as indicated below: abdominal pain (1, 4, 5); reflux syndrome (2, 3); diarrhea syndrome (11, 12, 14); indigestion syndrome (6, 7, 8, 9); constipation syndrome (10, 13, 15) and overall GSRS (1-15). The data is presented for participants with worsening of symptoms in \>=2 levels.
| Participants | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID |
|---|---|---|---|---|---|---|---|
| Pain/discomfort in upper abdomen, Day 7 | 0 | 0 | 2 | 2 | 0 | 0 | 0 |
| Heartburn, Day 7 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Acid reflux, Day 7 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Hunger pains, Day 7 | 0 | 0 | 1 | 0 | 1 | 1 | 0 |
| Nausea, Day 7 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Rumbling, Day 7 | 1 | 0 | 2 | 0 | 1 | 2 | 0 |
| Bloated, Day 7 | 2 | 0 | 1 | 1 | 0 | 3 | 0 |
| Burping, Day 7 | 1 | 0 | 1 | 0 | 0 | 2 | 0 |
| Passing gas or flatus, Day 7 | 1 | 1 | 1 | 1 | 0 | 2 | 0 |
| Constipation, Day 7 | 1 | 0 | 3 | 4 | 3 | 0 | 0 |
| Diarrhea, Day 7 | 0 | 0 | 2 | 3 | 4 | 4 | 0 |
| Loose stools, Day 7 | 1 | 0 | 3 | 4 | 3 | 3 | 0 |
| Hard stools, Day 7 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Urgent need to have bowel movement, Day 7 | 1 | 0 | 2 | 1 | 2 | 2 | 0 |
| Sensatn not complete empty bowels, Day 7 | 0 | 0 | 2 | 2 | 3 | 2 | 0 |
| Abdominal pain, Day 7 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Reflux syndrome, Day 7 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Indigestion syndrome, Day 7 | 1 | 0 | 1 | 0 | 0 | 2 | 0 |
| Constipation syndrome, Day 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Diarrhea syndrome, Day 7 | 0 | 0 | 2 | 3 | 2 | 2 | 0 |
| Overall GSRS, Day 7 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Pain/discomfort in upper abdomen, Day 14 | 1 | 1 | 2 | 1 | 1 | 1 | 1 |
| Heartburn, Day 14 | 1 | 0 | 2 | 0 | 0 | 0 | 0 |
| Acid reflux, Day 14 | 1 | 1 | 1 | 0 | 0 | 1 | 0 |
| Hunger pains, Day 14 | 0 | 0 | 2 | 2 | 0 | 2 | 0 |
| Nausea, Day 14 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Rumbling, Day 14 | 1 | 1 | 2 | 1 | 0 | 2 | 0 |
| Bloated, Day 14 | 2 | 1 | 2 | 1 | 0 | 3 | 00 |
| Burping, Day 14 | 1 | 1 | 1 | 0 | 0 | 2 | 0 |
| Passing gas or flatus, Day 14 | 0 | 1 | 2 | 2 | 0 | 2 | 0 |
| Constipation, Day 14 | 0 | 1 | 1 | 0 | 0 | 2 | 0 |
| Diarrhea, Day 14 | 1 | 0 | 4 | 3 | 2 | 5 | 0 |
| Loose stools, Day 14 | 1 | 1 | 3 | 2 | 3 | 3 | 0 |
| Hard stools, Day 14 | 0 | 0 | 2 | 0 | 0 | 1 | 0 |
| Urgent need to have bowel movement, Day 14 | 1 | 1 | 4 | 2 | 3 | 3 | 0 |
| Sensation not complete empty bowels, Day 14 | 0 | 0 | 3 | 2 | 3 | 2 | 0 |
| Abdominal pain, Day 14 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Reflux syndrome, Day 14 | 1 | 0 | 1 | 0 | 0 | 1 | 0 |
| Indigestion syndrome, Day 14 | 0 | 1 | 1 | 1 | 0 | 2 | 0 |
| Constipation syndrome, Day 14 | 0 | 0 | 2 | 0 | 0 | 2 | 0 |
| Diarrhea syndrome, Day 14 | 0 | 0 | 3 | 2 | 1 | 3 | 0 |
| Overall GSRS, Day 14 | 0 | 0 | 1 | 1 | 0 | 2 | 0 |
Testing cards were provided to participants for assessments. Participants with abnormal not clinically significant and abnormal clinically significant is presented. The Day -1 sample was obtained any time starting Day -2 and prior to GSK2330672 dosing on Day 1. The Day 14 sample was collected any time after dosing on Day 14 and prior to discharge on Day 15.
| Participants | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID | Run-in Only |
|---|---|---|---|---|---|---|---|---|
| Abnormal not clinically significant | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 |
| Abnormal clinically significant | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
The first occurrence of the maximum observed plasma concentration determined directly from the raw concentration-time data. Statistics for geometric least square mean provided.
| Nanograms per milliliter (ng/mL) | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID |
|---|---|---|---|---|---|---|---|
| PK Parameters for Metformin Steady State PK Parameters When Co-dosed With GSK2330672, Sitagliptin or Placebo-maximum Observed Concentration (Cmax) | 1102.2 ± 26.92 | 1289.3 ± 41.81 | 1219.9 ± 23.76 | 1160.0 ± 18.64 | 1378.8 ± 22.77 | 1376.6 ± 21.70 | 1223.5 ± 27.36 |
The time at which Cmax observed was determined directly from the raw concentration-time data.
| Hour | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID |
|---|---|---|---|---|---|---|---|
| PK Parameters for Metformin Steady State PK Parameters When Co-dosed With GSK2330672, Sitagliptin or Placebo-time of Occurrence of Cmax (Tmax) | 1.510 (1.00 to 4.00) | 1.000 (1.00 to 1.50) | 1.000 (0.50 to 3.98) | 1.050 (1.00 to 1.50) | 1.750 (0.50 to 4.00) | 1.500 (1.00 to 4.00) | 2.050 (1.00 to 4.02) |
PK population. Only those participants available at the specified time points were analyzed.
| Hour×ng/mL | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID |
|---|---|---|---|---|---|---|---|
| PK Parameters for Metformin Steady State PK Parameters When Co-dosed With GSK2330672, Sitagliptin or Placebo-area Under the Concentration-time Curve Over the Dosing Interval of 10 Hours (AUC[0-10]) | 6805.8 ± 19.70 | 5982.0 ± 34.72 | 7066.2 ± 25.80 | 7066.5 ± 16.09 | 8090.5 ± 33.06 | 8375.3 ± 32.78 | 8425.4 ± 28.11 |
Data for fasting low-density cholesterol (LDL) cholesterol, high-density cholesterol (HDL) cholesterol, total cholesterol, non-HDL cholesterol and triglycerides is presented. Participants withdrawing early were excluded. Results were based on an ANCOVA model: Log(post-Baseline) - Log(Baseline) = Log(Baseline) + treatment + concomitant use of lipid lowering drugs.
| Ratio | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID |
|---|---|---|---|---|---|---|---|
| Cholesterol, Day 7 | 0.95 ± 10.9 | 0.99 ± 12.1 | 0.84 ± 12.4 | 0.84 ± 13.7 | 0.74 ± 11.0 | 0.80 ± 3.7 | 0.97 ± 9.8 |
| Cholesterol, Day 14 | 0.95 ± 13.1 | 0.98 ± 14.2 | 0.81 ± 20.8 | 0.83 ± 18.5 | 0.75 ± 8.8 | 0.75 ± 6.7 | 0.92 ± 11.1 |
| HDL cholesterol, Day 7 | 1.00 ± 7.3 | 1.08 ± 12.8 | 1.05 ± 8.9 | 0.97 ± 8.0 | 0.95 ± 11.4 | 1.09 ± 15.7 | 0.97 ± 9.0 |
| HDL cholesterol, Day 14 | 0.99 ± 6.5 | 1.11 ± 1.5 | 1.02 ± 4.0 | 0.97 ± 8.8 | 0.96 ± 11.4 | 1.01 ± 11.6 | 0.97 ± 10.2 |
| LDL cholesterol, Day 7 | 0.97 ± 14.6 | 0.89 ± 6.4 | 0.77 ± 21.1 | 0.73 ± 21.5 | 0.58 ± 21.2 | 0.71 ± 6.5 | 1.00 ± 10.5 |
| LDL cholesterol, Day 14 | 0.94 ± 17.6 | 0.80 ± 4.2 | 0.69 ± 23.1 | 0.72 ± 23.7 | 0.60 ± 15.0 | 0.67 ± 16.3 | 0.92 ± 15.3 |
| Non-HDL Cholesterol, Day 7 | 0.93 ± 13.8 | 0.96 ± 12.6 | 0.78 ± 18.2 | 0.80 ± 18.2 | 0.65 ± 12.0 | 0.73 ± 5.1 | 0.98 ± 11.9 |
| Non-HDL Cholesterol, Day 14 | 0.94 ± 17.7 | 0.94 ± 17.5 | 0.74 ± 29.7 | 0.78 ± 23.7 | 0.67 ± 7.2 | 0.68 ± 8.6 | 0.90 ± 15.1 |
| Triglycerides, Day 7 | 0.85 ± 20.6 | 1.07 ± 51.2 | 0.93 ± 18.8 | 1.11 ± 24.5 | 0.98 ± 19.8 | 0.93 ± 16.3 | 0.79 ± 32.7 |
| Triglycerides, Day 14 | 0.85 ± 23.0 | 1.21 ± 63.3 | 0.96 ± 35.8 | 1.07 ± 34.3 | 1.00 ± 16.6 | 1.00 ± 23.7 | 0.74 ± 34.5 |
Data for fasting apolipoprotein B is presented. Participants withdrawing early were excluded. Results were based on an ANCOVA model: Log(post-Baseline) - Log(Baseline) = Log(Baseline) + treatment + concomitant use of lipid lowering drugs.
| Ratio | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID |
|---|---|---|---|---|---|---|---|
| Day 7 | 0.97 ± 10.6 | 0.95 ± 5.9 | 0.78 ± 13.9 | 0.81 ± 13.1 | 0.69 ± 12.0 | 0.76 ± 3.8 | 0.96 ± 10.3 |
| Day 14 | 0.93 ± 14.2 | 0.85 ± 6.7 | 0.75 ± 19.0 | 0.78 ± 19.6 | 0.67 ± 14.9 | 0.69 ± 9.3 | 0.88 ± 15.5 |
The first occurrence of the maximum observed plasma concentration determined directly from the raw concentration-time data following the first and second dose of sitagliptin on Day 14 (Cmax1 and Cmax2).
| Ng/mL | Sitagliptin 50 mg BID |
|---|---|
| Cmax 1 | 238.2 ± 26.20 |
| Cmax 2 | 188.5 ± 25.34 |
The time at which Cmax was observed by determining directly from the raw concentration-time data following the first and second dose of sitagliptin on Day 14 (Tmax1 and Tmax2). If data permits, Tmax2 was defined as the time of Cmax following the second dose of sitagliptin.
| Hour | Sitagliptin 50 mg BID |
|---|---|
| Tmax 1 | 2.000 (1.00 to 3.98) |
| Tmax 2 | 3.050 (2.98 to 4.07) |
The AUC(0-10) following the first dose and prior to the second dose of sitagliptin was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations.
| Hour×ng/mL | Sitagliptin 50 mg BID |
|---|---|
| Sitagliptin Steady State PK Parameters When Co-dosed With Metformin-AUC(0-10) | 1473.5 ± 22.45 |
Collected over AEs and SAEs were collected from run-in period until the follow-up contact (7-10 days after discharge). SAEs and non-SAE were reported from treatment period only (up to 14 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/13 (0%) | 0/13 (0%) | 9/13 (69.2%) |
| GSK2330672 10 mg BID | 0/5 (0%) | 1/5 (20%) | 3/5 (60%) |
| GSK2330672 20 mg BID | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| GSK2330672 30 mg BID | 0/9 (0%) | 0/9 (0%) | 5/9 (55.6%) |
| GSK2330672 60 mg BID | 0/9 (0%) | 0/9 (0%) | 8/9 (88.9%) |
| GSK2330672 90 mg BID | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| Sitagliptin 50 mg BID | 0/13 (0%) | 0/13 (0%) | 8/13 (61.5%) |
| Event | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID |
|---|---|---|---|---|---|---|---|
| Arrhythmia supraventricularCardiac disorders | 0/13 | 1/5 | 0/5 | 0/9 | 0/9 | 0/10 | 0/13 |
| Event | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID |
|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 4/13 | 2/5 | 5/5 | 2/9 | 7/9 | 6/10 | 2/13 |
| Abdominal painGastrointestinal disorders | 2/13 | 1/5 | 2/5 | 2/9 | 1/9 | 2/10 | 1/13 |
| FlatulenceGastrointestinal disorders | 1/13 | 0/5 | 1/5 | 0/9 | 1/9 | 3/10 | 1/13 |
| Faeces softGastrointestinal disorders | 1/13 | 0/5 | 0/5 | 2/9 | 1/9 | 2/10 | 0/13 |
| NauseaGastrointestinal disorders | 1/13 | 0/5 | 0/5 | 0/9 | 2/9 | 0/10 | 1/13 |
| HeadacheNervous system disorders | 2/13 | 0/5 | 0/5 | 0/9 | 2/9 | 1/10 | 0/13 |
| Viral infectionInfections and infestations | 0/13 | 0/5 | 0/5 | 0/9 | 2/9 | 0/10 | 0/13 |
| DyspepsiaGastrointestinal disorders | 0/13 | 1/5 | 1/5 | 0/9 | 0/9 | 0/10 | 2/13 |
| ProctalgiaGastrointestinal disorders | 0/13 | 1/5 | 0/5 | 0/9 | 1/9 | 1/10 | 0/13 |
| EructationGastrointestinal disorders | 1/13 | 1/5 | 0/5 | 0/9 | 0/9 | 0/10 | 0/13 |
| Age, Continuous(Years) | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID | Run-in Only | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 52.1 ± 6.97 | 54.0 ± 4.30 | 56.2 ± 8.50 | 57.1 ± 5.86 | 55.0 ± 4.27 | 54.8 ± 7.47 | 53.7 ± 6.79 | 55.5 ± 3.51 | 54.5 ± 6.20 |
| Sex: Female, Male(Participants) | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID | Run-in Only | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 3 | 4 | 2 | 6 | 4 | 5 | 3 | 31 |
| Male | 9 | 2 | 1 | 7 | 3 | 6 | 8 | 3 | 39 |
| Race (NIH/OMB)(Participants) | Placebo | GSK2330672 10 mg BID | GSK2330672 20 mg BID | GSK2330672 30 mg BID | GSK2330672 60 mg BID | GSK2330672 90 mg BID | Sitagliptin 50 mg BID | Run-in Only | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 3 |
| Black or African American | 3 | 1 | 0 | 1 | 3 | 0 | 3 | 1 | 12 |
| White | 10 | 4 | 4 | 8 | 4 | 9 | 10 | 5 | 54 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Aug 2014 to primary completion in Jan 2015, 5 months.
Results were first posted in Nov 2017, 2 years 9 months after primary completion. A results delay was requested in May 2015.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 5 months is below that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linerixibat